Cargando…

Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model

The development of new combinations of antimalarial drugs is urgently needed to prevent the spread of parasites resistant to drugs in clinical use and contribute to the control and eradication of malaria. In this work, we evaluated a standardized humanized mouse model of erythrocyte asexual stages o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Demarta-Gatsi, Claudia, Andenmatten, Nicole, Jiménez-Díaz, María-Belén, Gobeau, Nathalie, Cherkaoui-Rabti, Mohammed H., Fuchs, Aline, Díaz, Pablo, Berja, Sandra, Sánchez, Rebeca, Gómez, Hazel, Ruiz, Estíbaliz, Sainz, Paula, Salazar, Eider, Gil-Merino, Rodrigo, Mendoza, Luis Manuel, Eguizabal, Cristina, Leroy, Didier, Moehrle, Joerg J., Tornesi, Belen, Angulo-Barturen, Iñigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2023
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269072/ https://www.ncbi.nlm.nih.gov/pubmed/37133382 http://dx.doi.org/10.1128/aac.01574-22

Ejemplares similares

Using Cryopreserved Plasmodium falciparum Sporozoites in a Humanized Mouse Model to Study Early Malaria Infection Processes and Test Prophylactic Treatments
por: Jiménez-Díaz, María-Belén, et al.
Publicado: (2023)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development
por: McCarthy, James S., et al.
Publicado: (2016)

New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
por: Wicha, Sebastian G., et al.
Publicado: (2022)

Malarial PI4K inhibitor induced diaphragmatic hernias in rat: Potential link with mammalian kinase inhibition
por: Demarta‐Gatsi, Claudia, et al.
Publicado: (2022)

Macrocyclic Peptidomimetic Plasmepsin X Inhibitors with Potent In Vitro and In Vivo Antimalarial Activity
por: Kovada, Vadims, et al.
Publicado: (2023)

A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery
por: Jiménez-Díaz, María Belén, et al.
Publicado: (2013)

Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial
por: Thakkar, Nilay, et al.
Publicado: (2018)

Vector saliva controlled inflammatory response of the host may represent the Achilles heel during pathogen transmission
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2021)

A novel class of fast‐acting antimalarial agents: Substituted 15‐membered azalides
por: Peric, Mihaela, et al.
Publicado: (2020)

In Vitro Antimalarial Activity of Inhibitors of the Human GTPase Rac1
por: Parapini, Silvia, et al.
Publicado: (2022)

Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
por: McCarthy, James S., et al.
Publicado: (2019)

Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
por: de Vries, Laura E., et al.
Publicado: (2022)

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission
por: Kuhen, Kelli L., et al.
Publicado: (2014)

Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum
por: McCarthy, James S., et al.
Publicado: (2021)

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials
por: Norcross, Neil R., et al.
Publicado: (2016)

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling
por: Le Bihan, Amélie, et al.
Publicado: (2016)

Randomized Controlled Trial of the Electrocardiographic Effects of Four Antimalarials for Pregnant Women with Uncomplicated Malaria on the Thailand-Myanmar Border
por: Saito, Makoto, et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
por: Sinxadi, Phumla, et al.
Publicado: (2020)

Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study
por: Chughlay, Mohamed Farouk, et al.
Publicado: (2021)

Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay
por: Linares, María, et al.
Publicado: (2015)

Pinch biopsy: A modified punch biopsy technique to avoid histological artifacts and surgical tools
por: Rodríguez-Lomba, Enrique, et al.
Publicado: (2021)

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020)

Pyrazoleamide compounds are potent antimalarials that target Na(+) homeostasis in intraerythrocytic Plasmodium falciparum
por: Vaidya, Akhil B., et al.
Publicado: (2014)

Parasite-Host Dynamics throughout Antimalarial Drug Development Stages Complicate the Translation of Parasite Clearance
por: Burgert, Lydia, et al.
Publicado: (2021)

Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity
por: Kokkonda, Sreekanth, et al.
Publicado: (2016)

Immunological memory to blood-stage malaria infection is controlled by the histamine releasing factor (HRF) of the parasite
por: Demarta-Gatsi, Claudia, et al.
Publicado: (2017)

A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
por: Leong, F. Joel, et al.
Publicado: (2014)

A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria
por: Cherkaoui‐Rbati, Mohammed H., et al.
Publicado: (2022)

Co-prescription patterns of cardiovascular preventive treatments: a cross-sectional study in the Aragon worker’ health study (Spain)
por: Aguilar-Palacio, Isabel, et al.
Publicado: (2019)

Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase
por: Palencia, Andrés, et al.
Publicado: (2016)

Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case–control study
por: Erviti, Juan, et al.
Publicado: (2013)

Re-orienting anti-malarial drug development to better serve pregnant women
por: El Gaaloul, Myriam, et al.
Publicado: (2022)

Development of New Strategies for Malaria Chemoprophylaxis: From Monoclonal Antibodies to Long-Acting Injectable Drugs
por: Moehrle, Joerg J.
Publicado: (2022)

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development
por: Burgert, Lydia, et al.
Publicado: (2020)

First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials
por: Moehrle, Joerg J, et al.
Publicado: (2013)

Synthesis and Antimalarial Activity of Mallatojaponin C and Related Compounds
por: Eaton, Alexander L., et al.
Publicado: (2016)

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
por: Diaz, R, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_754pbpt3jf4cqovq39u8m6t8te